Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

[2] The candidate drug was discovered by Cambridge Antibody Technology in collaboration with Abbott.

The Psoriasis Area Severity Index (PASI) was reduced significantly better than under the comparator treatments.

On January 15, 2011, Abbott announced the withdrawal of its application to the US FDA and European regulators for briakinumab.

This is the second candidate from a deal with Cambridge Antibody Technology that Abbott have taken to late-stage clinical trials.